Drug Companies' Evidence to Justify Advertising

V. A. Wade; P. R. Mansfield; P. J. Mcdonald

doi:10.1016/S0140-6736(89)91862-X

Drug Companies' Evidence to Justify Advertising

V. A. Wade, P. R. Mansfield, P. J. Mcdonald

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Ten international pharmaceutical companies were asked by letter to supply their best evidence in support of marketing claims for seventeen products. Fifteen replies were received. Seven replies cited a total of 67 references: 31 contained relevant original data and only 13 were controlled trials, all of which had serious methodological flaws. There were four reports of changes in advertising claims and one company ceased marketing nikethamide in the third world. Standards of evidence used to justify advertising claims are inadequate.

Original language	English
Pages (from-to)	1261-1264
Number of pages	4
Journal	The Lancet
Volume	334
Issue number	8674
DOIs	https://doi.org/10.1016/S0140-6736(89)91862-X
Publication status	Published - 25 Nov 1989

Access to Document

10.1016/S0140-6736(89)91862-XLicence: In Copyright

Cite this

@article{738624a63d2e4696ac84257b30a12526,

title = "Drug Companies' Evidence to Justify Advertising",

abstract = "Ten international pharmaceutical companies were asked by letter to supply their best evidence in support of marketing claims for seventeen products. Fifteen replies were received. Seven replies cited a total of 67 references: 31 contained relevant original data and only 13 were controlled trials, all of which had serious methodological flaws. There were four reports of changes in advertising claims and one company ceased marketing nikethamide in the third world. Standards of evidence used to justify advertising claims are inadequate.",

author = "Wade, {V. A.} and Mansfield, {P. R.} and Mcdonald, {P. J.}",

year = "1989",

month = nov,

day = "25",

doi = "10.1016/S0140-6736(89)91862-X",

language = "English",

volume = "334",

pages = "1261--1264",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Lancet",

number = "8674",

}

TY - JOUR

T1 - Drug Companies' Evidence to Justify Advertising

AU - Wade, V. A.

AU - Mansfield, P. R.

AU - Mcdonald, P. J.

PY - 1989/11/25

Y1 - 1989/11/25

N2 - Ten international pharmaceutical companies were asked by letter to supply their best evidence in support of marketing claims for seventeen products. Fifteen replies were received. Seven replies cited a total of 67 references: 31 contained relevant original data and only 13 were controlled trials, all of which had serious methodological flaws. There were four reports of changes in advertising claims and one company ceased marketing nikethamide in the third world. Standards of evidence used to justify advertising claims are inadequate.

AB - Ten international pharmaceutical companies were asked by letter to supply their best evidence in support of marketing claims for seventeen products. Fifteen replies were received. Seven replies cited a total of 67 references: 31 contained relevant original data and only 13 were controlled trials, all of which had serious methodological flaws. There were four reports of changes in advertising claims and one company ceased marketing nikethamide in the third world. Standards of evidence used to justify advertising claims are inadequate.

UR - http://www.scopus.com/inward/record.url?scp=0024463657&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(89)91862-X

DO - 10.1016/S0140-6736(89)91862-X

M3 - Article

C2 - 2573769

AN - SCOPUS:0024463657

SN - 0140-6736

VL - 334

SP - 1261

EP - 1264

JO - The Lancet

JF - The Lancet

IS - 8674

ER -

Drug Companies' Evidence to Justify Advertising

Abstract

Access to Document

Other files and links

Fingerprint

Cite this